Although the first CETP inhibitor (Torcetrapib) evaluated in the ILLUMINATE trial was associated with increased mortality rates due to infection and cancer26, the subsequent CETP inhibitors (Anacetrapib, evacetrapib, and dalcetrapib) seem to be safe27–29. The gene discussed is CETP; the disease is infection.